{"nctId":"NCT02837952","briefTitle":"A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain","startDateStruct":{"date":"2016-08-31","type":"ACTUAL"},"conditions":["Pain"],"count":123,"armGroups":[{"label":"Fixed Dose Combination(FDC) IBU/APAP 250 mg/500 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: FDC IBU/APAP 250 mg/500 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"FDC IBU/APAP 250 mg/500 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n1. Males and females 18 years to 40 years of age (inclusive).\n2. Outpatients who have undergone surgical extraction of 3 or more third molars, of which at least 2 must be a partial or complete bony mandibular impaction.\n3. Subject must have at least moderate pain on the 4 point categorical scale, confirmed by at least 50 mm on the 100 mm VAS PSR scale within approximately 5 hours (ie, less than or equal to 5 hours, 15 minutes) after surgery is completed.\n4. In general good health and have no contraindications to the study or rescue medication.\n\nExclusion Criteria\n\n1. Presence or history of any significant hepatic, renal, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorder determined by the Investigator to place the subject at increased risk, including the presence or history within 2 years of screening of the following medical conditions/disorders:\n\n   * Gastrointestinal ulcer or gastrointestinal bleeding;\n   * Paralytic ileus or other gastrointestinal obstructive disorders;\n   * Bleeding disorder.\n2. Hypersensitivity to ibuprofen, naproxen, aspirin, or any other NSAID; or to APAP, tramadol, other opioids, or to their combinations.\n3. Prior use of any type of analgesic or NSAID within five half lives of that drug or less before taking the first dose of investigational product, except for pre anesthetic medication and anesthesia for the procedure.\n\n   .","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 24 Hours Post-dose (SPID11 [0-24])","description":"Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11 \\[0-24\\]: Time-weighted sum of Pain Intensity Difference (PID) scores over 24 hours. SPID11 score range was -120 (worst score) to 240 (best score) for SPID 0-24. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.13","spread":"9.426"},{"groupId":"OG001","value":"64.76","spread":"6.676"}]}]}]},{"type":"SECONDARY","title":"Time-weighted Sum of Pain Intensity Difference Score on 11-Point Numerical Scale (SPID11) From 0 to 8, 6 to 8, 0 to 16, 8 to 16 and 0 to 48 Hours Post-dose","description":"Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11 for various time intervals: Time-weighted sum of PID scores over time intervals of 0-8 hours, 6-8 hours, 0-16 hours, 8-16 hours and 0-48 hours. SPID11 score range was -40 (worst score) to 80 (best score) for (SPID11 \\[0-8\\]), -15 (worst score) to 30 (best score) for (SPID11 \\[6-8\\]), -80 (worst score) to 160 (best score) for (SPID11 \\[0-16\\]), -45 (worst score) to 90 (best score) for (SPID11 \\[8-16\\]), -240 (worst score) to 480 (best score) for (SPID11 \\[0-48\\]). PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.12","spread":"2.708"},{"groupId":"OG001","value":"23.33","spread":"1.918"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.46","spread":"1.123"},{"groupId":"OG001","value":"6.45","spread":"0.795"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.24","spread":"6.028"},{"groupId":"OG001","value":"45.43","spread":"4.270"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.68","spread":"3.794"},{"groupId":"OG001","value":"23.64","spread":"2.687"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.97","spread":"19.668"},{"groupId":"OG001","value":"123.69","spread":"13.930"}]}]}]},{"type":"SECONDARY","title":"Duration of Relief After First Dose","description":"Duration of relief (in minutes) was defined as the time interval from the administration of first dose of study drug up to the administration of a rescue medication or discontinuation of the participant from the study due to lack of efficacy or administration of second dose of study drug, whichever occurred first. If prior to taking rescue medication or secondary dose, a participant discontinued early from the study due to other reasons, the time was censored at time when the participant last performed a study evaluation prior to the discontinuation.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of \"Meaningful\" Pain Relief After First Dose","description":"Using the double stopwatch method, participants started two stopwatches soon after dosing. Participants evaluated time to meaningful relief after first dose by stopping the second stopwatch labelled as \"meaningful relief\" at the moment they first began to experience meaningful relief after the administration of first dose and prior to the administration of second dose of study drug. The stopwatch was active for up to 8 hours after dosing or until stopped by the participant, or until second dose or a rescue medication whichever is administered first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165.9","spread":null},{"groupId":"OG001","value":"59.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":["Nausea","Vomiting","Dizziness","Headache","Vision blurred"]}}}